Tsering Gyalpo Lama Tamang, MD

Biografía

I began my medical training at Kathmandu Medical College in Kathmandu, where I earned my medical degree and completed my internship. After moving to the United States, I completed my internal medicine residency at Maimonides Medical Center in New York in 2017. Following residency, I completed a clinical fellowship in hematology and oncology at UC Irvine in 2020.

Acerca de mi práctica médica

By nature, I am compassionate, and I believe my happiness is closely tied to the well-being of those around me — an outlook shaped by my upbringing that continues to guide my work as a physician. Cancer is one of the most emotionally challenging diagnoses a person can face, and from the moment of diagnosis, every moment becomes precious.

Throughout medical school and residency, I witnessed the immense strength, courage, and hope that patients and their families bring to this journey. I also observed firsthand the critical role that physicians and care teams play in supporting them. Seeing how a strong support system can transform the cancer journey inspired me to pursue a career in hematology and oncology.

After completing my fellowship at UC Irvine, I joined Kaiser Permanente because its team-based care allows me to focus on what matters most: coordinated, member-centered cancer care. The collaboration among specialties ensures that members receive timely, comprehensive treatment. I care for a wide range of general oncology and benign hematology conditions. I value building long-term, meaningful relationships with members. I believe we are all part of one big family, and that love and compassion are essential for human well-being. For this reason, I strive to treat the whole person, not just the disease, with care, empathy, and respect.

Multidisciplinary Teams

I believe that effective care depends on collaboration and teamwork. I participate in local and regional multidisciplinary tumor boards to ensure that members receive comprehensive, coordinated care, with the goal of improving care and supporting positive outcomes for members.

Research

Oncology is constantly evolving, with advances in cancer biology and therapies shaping care every day. I view research as essential for improving both the effectiveness and tolerability of treatments. My residency and fellowship training have prepared me to deliver high-quality care that is based on evidence and current research. I prioritize staying current with the latest advancements to provide positive outcomes for members.

Publications and Abstracts 

1. Lama Tamang, T. G., Tang, L., Chuan, J., Patel, R., and Wong, N. (2014). “Examining risk factor goal attainment and adherence to treatment among US heart failure patients: The National Health and Nutrition Examination Survey 2007–2010.” American Journal of Cardiovascular Drugs, 14(1), 41–49. PMID: 24105016

2. Lama Tamang, T. G., Shuster, M., and Chandra, A. (2016). “Primary hepatic osteosarcoma: A rare cause of primary liver tumor.” Clinical Medicine Insights: Case Reports, 9(1), 31–33. PMID: PMC4827792

3. Lama Tamang, T. G., Barola, S., and Chandra, A. (2015). “Assessing bacterial isolates in bloodstream infections and trend of the antimicrobial resistance in the hematological and solid malignancies.” Blood, 126(23), 5628–5628.

4. Singh, P., Sinha, A., Lama Tamang, T. G., Chandra, A. B., and Huang, Y. J. (2017). “Abiraterone-associated fulminant liver failure.” American Journal of Therapeutics. doi:10.1097/MJT.0000000000000597. PMID: 28452846

5. Tamang, T. G. L., et al. (2017). “Prostatic lymphoma masquerading as urinary retention and hematuria with review of literature.” World Journal of Oncology, 8(4), 132–135. PMID: 29147449

6. Lama Tamang, T. G., Singh, P., and Chandra, A. (2016). “Chronic myeloid leukemia in a patient with multiple sclerosis treated with interferon-beta-1a.” Journal of Medical Cases.

7. Lama Tamang, T. G. L., Fruehauf, J. P., and Ejadi, S. (2020). “Single-institution outcomes with less than two-year anti-PD-1 antibody therapy in metastatic melanoma.” Journal of Clinical Oncology, 38, e22001–e.

8. Lama Tamang, T. G. L., Kyung, D., Eisenbud, L., Tang, T., Mehta, R. S., and Parajuli, R. (2020). “Use of alpelisib in the treatment of hormone receptor-positive metastatic breast cancer: An institutional experience.” Journal of Clinical Oncology, 38, e15216–e.

9. Eisenbud, L., Lama Tamang, T. G. L., Cheng, C., et al. (2020). “Relationship of the breast ductal carcinoma in situ (DCIS) immune microenvironment with clinicopathological features: An institutional experience.” Journal of Clinical Oncology, 38, e12565–e.

10. Tsering Gyalpo Lama, Kyung, D., and O’Brien, S. (2020). “Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.” Expert Review of Hematology, 13(8), 871–883. doi:10.1080/17474086.2020.1797482

Cómo vivo bien

Outside of medicine, I value spending quality time with family and friends. I enjoy traveling, hiking, painting, and practicing meditation activities that help me recharge and bring renewed energy and focus to my work with members.